Andrea Favre-Bulle

6PUBLICATIONS
15CO-AUTHORS
Preventative health careEconomic development policyHealth promotionCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 11, 2026
Cost-effectiveness analysis of pneumococcal vaccination of at-risk and high-risk adults aged 18-64 years in Switzerland using PCV21.

|Feb 18, 2026
Delta price cost-effectiveness analysis of PCV21 vs PCV20 use in adults aged ≥65 years in Switzerland.

Muloongo Simuzingili, Andrea Favre-Bulle, Thomas Mutschler

|Jul 14, 2025
Increasing HPV vaccination coverage in Switzerland: a return-on-investment analysis.

Nikolaos Kotsopoulos, Mark P Connolly, Selim Nur

|Jun 21, 2024
Assessing the fiscal consequences of novel and existing treatments for triple negative breast cancer in Switzerland by applying a government perspective framework.

Cillian Copeland, Nikos Kotsopoulos, Andrea Favre-Bulle

|Nov 24, 2023
Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland.

Andrea Favre-Bulle, Min Huang, Amin Haiderali

|Feb 07, 2023
Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland.

Andrea Favre-Bulle, Goran Bencina, Shujing Zhang

Pageof 1

Frequent Collaborators

2 joint publications

Goran Bencina

2 joint publications

Kwame Owusu-Edusei

2 joint publications

Arjun Bhadhuri

2 joint publications

Nikos Kotsopoulos